University of Chicago: Lymphoma trials

The registry lists 11 Lymphoma studies with University of Chicago as lead sponsor. 1 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 3Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingNCT07294677Phase 1/2
• A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaTerminatedNCT04722601Phase 1/2Results posted
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)TerminatedNCT03990961Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell LymphomaTerminatedNCT02420210Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin LymphomaActive, not recruitingNCT05019976Not applicable
• Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
• Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
• Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00004145Phase 2